Evaluation of GSK5862611, an anti‐Sortilin antibody, in hiPSC‐derived complex cellular models harbouring TDP43 G298S risk variant

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-12-01
DOI
https://doi.org/10.1002/alz70855_096500
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of GSK5862611, an anti‐Sortilin antibody, in hiPSC‐derived complex cellular models harbouring TDP43 G298S risk variant

Thomas Westergard
Alzheimer s & Dementia
Amyotrophic Lateral Sclerosis Research
article

Evaluation of GSK5862611, an anti‐Sortilin antibody, in hiPSC‐derived complex cellular models harbouring TDP43 G298S risk variant

Thomas Westergard
article en

Abstract

No abstract available for this paper.
Alzheimer s & DementiaVol. 21(S1)
GlaxoSmithKline (United States) (US)
Openalex Percentile: Top 32%
Amyotrophic Lateral Sclerosis Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Evaluation of GSK5862611, an anti‐Sortilin antibody, in hiPSC‐derived complex cellular models harbouring TDP43 G298S risk variant — Thomas Westergard · Alzheimer s & Dementia (2025) | TGRS Research Map | TGRS